B+
Bull case
30%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-06-26 · RankAlpha Sentiment Codex
BLFS
BioLife SolutionsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is still that BioLife has a focused recurring-revenue CGT tools model, solid Q1 growth, reaffirmed 2026 guidance, and increasing embed depth across commercial therapies and late-stage trials [#SEC-8K-2026-05-07].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.2.
What can break
BPM represents more than 85% of revenue and the top 20 BPM customers account for about 80% of BPM sales, leaving BioLife exposed to customer concentration and program timing risk [#PR-EARNINGS-2026-05-08].
Momentum
85
Value
56
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.50 · Bull $33.00 · Bear $23.50Analysis 2026-06-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $31.13
Why
Momentum85 · Δ7d -8.9
Value56 · Δ7d -0.0
Sentiment45 · Δ7d +5.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.2.
Contradictions & invalidation
- • BPM represents more than 85% of revenue and the top 20 BPM customers account for about 80% of BPM sales, leaving BioLife exposed to customer concentration and program timing risk [#PR-EARNINGS-2026-05-08].
- • Demand visibility is tied to the CGT end market, so slower therapy approvals, indication expansions, or funding recovery would weaken the current growth framework implied by management commentary [#SEC-8K-2026-02-26] [#SEC-8K-2026-05-07].
- • The main bear point is that margin repair still depends on fixing bag-yield and product-mix pressure, while BPM remains highly concentrated in a limited customer set and the company has only sparse external coverage detail beyond company materials [#PR-EARNINGS-2026-05-08].
Catalyst clock
2026-08-06
Q1 growth and full-year outlook held
Lead driver: Sentiment · See AI snapshot
Momentum
85
9% active weight
Current posture
7d trendSoftening
Δ7d
-8.9
Δ21d
-8.9
Value
56
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
45
62% active weight
Current posture
7d trendImproving
Δ7d
+5.2
Δ21d
+4.6
Why this grade
Composite grade D. Momentum 85.0 / Value 56.0 / Sentiment 44.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-26. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$30.50
Analysis reference price unavailable
Analysis 2026-06-26 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$23.50
Analysis reference price unavailable
Analysis 2026-06-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.73B
Beta
1.93
Shares Out
48.91M
P/E (TTM) · Derived
-113.5
P/S (TTM)
13.72
P/FCF (TTM)
3795.89
Rev YoY
+21.5%
EPS YoY
-376.1%
Gross Margin
+64.8%
Op Margin
+2.9%
Net Debt
-$71.03M
Current Ratio
9.69
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data